Haypp's view on recent FDA nic pouch guidance & implications. As our US president notes, "responsible retail for nicotine pouch sales online, requires real structure and measurable controls, not good intentions."
https://t.co/2jkXsnDGIg
$HAYPP $PM $PMI $BATS $BTI $MO $IMB $TPB
Another important Reuters article looking at the effect of FDA's recent guidance, noting that this change "will potentially unleash hundreds more such products on the market in the coming weeks and months"
https://t.co/OTpS0aBqSx
$HAYPP $PM $PMI $MO $BATS $BTI $IMB $TPB $JTI
From the guidance:
...does not intend to prioritize enforcement of the premarket authorization requirement,
where the product:
• is subject to an application that is pending, and the application has been accepted and
filed ...and pending for more than 180 days;
$HAYPP
Haypp released Q1 26 results today, w/ topline momentum accelerating. Group sales up 24% YoY in cc driven by 40% nicotine pouch growth
The Q1 report w/ new disclosures incl. volume & GM by segment is available at:
https://t.co/tptJ83oOY0
$HAYPP
Our upcoming Q1 26 results will be released at 0745 Stockholm on 7 May, with a conference call webcast at 0900.
Consensus estimates from 4 IBs (Barclays, DB, DNBC, Pareto) are available at :
https://t.co/hVZwq77ikf
$HAYPP
Reuters FDA sources say delay in nicotine pouch accelerated reviews, “due to a cautious approach by agency reviewers…[as] the scientific evidence for speeding them through was not as clear-cut as expected.”
https://t.co/m1RFnqFqsl
$HAYPP $BATS $BTI $PM $MO $TPB $IMB $JTI
Haypp is pleased to announce that on! PLUS nicotine pouches, produced by Altria are now available on Haypp’s US sites https://t.co/UapkktTVzh and https://t.co/2sqHJK3Om4. See the link for more detail.
https://t.co/8ZEoNOh7IY
$HAYPP $MO
Positive developments from EESC on Euro TTD
"Together with the prevention of excessive tax increases, the principle of risk-proportionate taxation is at the heart of the committee's recommendations."
https://t.co/kzGJwmYc64
$HAYPP $PMI $BATS $BTI $JTI $IMB $STG $MO
Notable argument by the IMF that taxation should reflect harm. “Ideally, the level of taxation should reflect the degree of harm a product is likely to cause while still safeguarding overall revenue.”
https://t.co/zHxaSR4ypW
$HAYPP $PM $MO $BATS $BTI $IMB $JTI $TPB $STG
Another insightful argument explaining the resistance by some in tobacco control to offering consumers lower risk products than cigarettes that they switch to without coercion.
$HAYPP $PM $BATS $BTI $MO $IMB $JTI $TPB
The easiest play in tobacco control is also the dumbest. My new post on why the Irreconcilable Conflict Principle (a fancy version of the “scream test”) distorts science, policy and truth... with 8 examples.
https://t.co/Ix3HBig5D8
EU Health Commissioner @OliverVarhelyi is spreading absurd disinformation about tobacco and nicotine risks.
23 experts write to explain the damage to EU citizens and the credibility of EU policymaking.
CC: @vonderleyen, @steph_sejourne, @EU_Health
https://t.co/QIjasyzurR
An important critique by a prominent public health veteran of WHO's approach to smoking and reduced risk nicotine products and why it is flawed.
$HAYPP $PM $BATS $BTI $IMB $JTI $STG $MO
The WHO is a risk factor for cancer
https://t.co/JQk9t5qwm5
In a new Code Against Cancer, the World Health Organisation opposes the most effective and popular way to reduce the most important modifiable cancer risk, smoking.
So, what does that make WHO?
Our presentation slides and Excel with financial data can be found below. The transcript from the first CC will be posted here as well.
https://t.co/tptJ83pmNy
$HAYPP
Haypp announced its Q4 25 results earlier today. The report is available at the below link, with webcast of the presentation + Q&A at 0900 CET. A 2nd presentation + Q&A will be held at 1600 CET / 1000 Eastern.
https://t.co/LRC4Uo542v
$HAYPP
Haypp's Q4 2025 results presentation + Q&A will be webcast 13 Feb at 0900 CET w/ a 2nd webcast + Q&A at 1000 Eastern. Investors, analysts and media are invited to participate in the call using details in the link.
https://t.co/kFP5sdFyal
$HAYPP
A thought provoking article about science around nicotine products. "Instead of asking whether a claim is true, critics ask where the claimant sits in relation to the industry."
Conflict of Interest - Redefined...
https://t.co/2Ecx6i5fgR
$HAYPP $PM $MO $BATS $BTI $IMB $JTI